We read with interest the article by Li et al. first to report on COVID-19 in patients with chronic myeloid leukaemia (CML) [1]. They found an increased COVID-19 prevalence in CML patients of the Hubei region in China when compared to the prevalence of the general population of that region. Unfortunately, in this retrospective study, follow-up data were not provided and a direct control group was not included.